Maravai LifeSciences
MRVI
7.43
-0.42
-5.35%
Maravai LifeSciences
US · MRVI
#3116 by market cap
Listed 2020
7.43
-0.42
-5.35%
Live - 5344 symbols - heartbeat 364s ago
· 2026-10-07 19:54
After-hours
7.44
+0.13%
- Market cap
- 1.11B
- P/E (TTM)i
- -14.02
- P/Bi
- 5.41
- EPSi
- -0.90
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on MRVI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.9 percentage points.
Institutional ownership
- Held by institutions
- 100.03% +0.88pp
- Institutions
- 206 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund46.43%
Hedge Fund30.67%
VC/PE Fund13.52%
Private Company3.65%
Individual/Insider3.53%
Public Company3.14%
Insurance Company1.39%
Sovereign Wealth Fund0.43%
Family Office/Trust0.43%
Top holders as of 2026-06-30
GTCR LLC
13.52% · 20.15M sh
BlackRock
6.69% · 9.97M sh
Braidwell LP
5.84% · 8.70M sh
Millennium Management LLC
5.22% · 7.77M sh
12 West Capital Management LP
4.74% · 7.06M sh
Vanguard Capital Management, LLC
4.10% · 6.11M sh
Ophir Asset Management Pty Ltd
3.24% · 4.83M sh
Renaissance Technologies Corp.
3.09% · 4.61M sh
Deutsche Asset & Wealth Management
2.89% · 4.30M sh
First Eagle Investment Management, LLC
2.46% · 3.67M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| GTCR LLC | -- | 13.52% |
| Bernd Brust | Chief Executive Officer | 0.58% |
| Peter Leddy | Executive Vice President | 0.46% |
| Kevin Herde | Chief Financial Officer | 0.41% |
| William Martin | Chief Executive Officer | 0.25% |
| Gregory Lucier | Independent Director | 0.18% |
| Christine Dolan | Chief Operating Officer of Biologics Safety Testing | 0.18% |
| Robert Eckert | Chairperson | 0.17% |
| Rebecca Buzzeo | Chief Commercial Officer | 0.15% |
| Susannah Gray | Independent Director | 0.11% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -5,465 | $7.65 |
| 2026-09-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $7.32 |
| 2026-08-30 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -5,465 | $7.68 |
| 2026-08-09 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $6.23 |
| 2026-07-29 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -5,465 | $6.59 |
| 2026-07-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -29,250 | $5.92 |
| 2026-06-29 | Rajesh Asorpota | Chief Financial Officer | Sale to Issuer | -65,584 | $6.39 |
| 2026-06-09 | Kurt Oreshack | General Counsel | Automatic Disposition | -50,000 | $5.06–5.10 |
| 2026-06-09 | Kurt Oreshack | General Counsel | Intent to Sell (Form 144) | -25,000 | $5.10 |
| 2026-06-08 | Gregory Lucier | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-06-08 | Gregory Lucier | Independent Director | Other Disposition | -46,293 | -- |
| 2026-06-08 | Kurt Oreshack | General Counsel | Intent to Sell (Form 144) | -25,000 | $5.06 |
| 2026-06-07 | Bernd Brust | Chief Executive Officer | Sale to Issuer | -351,001 | $5.02 |
| 2026-05-25 | John DeFord | Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Constantine Mihas | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Sean Cunningham | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Gregory Lucier | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Susannah Gray | Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-25 | Luke Marker | Non-Independent Director | Other Acquisition | +46,293 | -- |
| 2026-05-14 | Kurt Oreshack | General Counsel | Other Acquisition | +776 | $2.84 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.